Signals of Change in the Management of Atopic Dermatitis
Premiere Date: Wednesday, March 3, 2021This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, March 3, 2022
Note: Credit Is No Longer Available
 | Jonathan I. Silverberg, MD, PhD, MPH (Moderator) Associate Professor of Dermatology Director of Clinical Research and Contact Dermatitis George Washington University School of Medicine and Health Sciences Washington, DC |
 | Zelma C. Chiesa Fuxench, MD, MSCE Assistant Professor of Dermatology Department of Dermatology University of Pennsylvania Perelman School of Medicine Philadelphia, PA |
 | Melinda Gooderham, MSc, MD, FRCPC Medical Director, SKiN Centre for Dermatology Assistant Professor, Department of Medicine Queen’s University Consultant Physician Peterborough Regional Health Centre Ontario, Canada |
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that effects up to 18% of children and up to 10% of adults and can have a substantial negative impact on the quality of life (QoL) of patients and their families. Its management is challenging at any age, with patients and caregivers often becoming overwhelmed by the chronic and relapsing nature of AD. Establishing disease severity is essential to inform treatment decisions, as is information on new clinical trial data for therapies such as oral Janus kinase (JAK) inhibitors. Thus, education that provides tools to establish disease severity and information on the development of new agents is warranted in order to mitigate the clinical and QoL impact of AD.
This enduring material blends faculty presentation and discussion to assist learners in applying clinical tools to establish disease severity, translating how new agents will impact clinical practice, and integrating patient preferences and treatment goals into shared decision-making (SDM).
At the end of this CE activity, participants should be able to:
- Apply clinical tools to establish disease severity to inform treatment decisions in patients with AD.
- Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
- Integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify clinical tools to establish disease severity to inform treatment decisions in patients with AD.
- Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
- Explain how to integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.
Supported by an educational grant from Pfizer Inc.
Allergists, dermatologists, PAs, nurse practitioners, nurses, pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Enduring: 0376-0000-21-044-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format:
Enduring material
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Silverberg reports that he receives grants from Galderma and Pfizer Inc. He is on the speakers bureau for Pfizer Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi. He is a consultant for AbbVie Inc.; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC.; BiomX; Bluefin Biomedicine; Bodewell; Boehringer-Ingelheim; Celgene Corporation; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; LEO Pharma Inc.; Luna; Menlo Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; and Sanofi.
Dr. Chiesa Fuxench reports she receives grants from Dermatology Foundation Career Development Award (PI). She receives research support from LEO Pharma Inc.; Menlo Therapeutics; Sanofi-Regeneron Pharmaceuticals Inc.; and Vanda Pharmaceuticals Inc. She serves as a consultant for AbbVie Inc.; Incyte: LEO Pharma Inc.; Sanofi-Regeneron Pharmaceuticals Inc.
Dr. Gooderham reports she receives research support from AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Arcutis Biotherapeutics; Bausch Health; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation; Coherus BioSciences; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline; Glenmark; Janssen Inc.; Kyowa Kirin Co., Ltd.; LEO Pharma Inc.; MedImmune; Merck & Co., Inc.; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; and UCB Canada Inc. She is on the speakers bureau for AbbVie Inc.; Actelion; Amgen Inc.; Bausch Health; Boehringer Ingelheim; Celgene Corporation; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma; Glenmark; Janssen Inc.; LEO Pharma Inc.; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Ltd.; and UCB Canada Inc. She is a consultant for AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Bausch Health; Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company; Janssen Inc.; Kyowa Kirin Co., Ltd.; Sanofi; Sun Pharmaceutical Industries Ltd.; and UCB Canada Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Noreen Iftikhar, MD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV2-112-030321-02
